Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Histone deacetylases (HDACs) are critical regulators of gene expression and are implicated in cancer development.
• HDAC inhibitors represent a promising class of anti-cancer agents.
• FK228 is a potent HDAC inhibitor with potential therapeutic applications.

Purpose of the Study:

• To investigate the in vitro effects of FK228 on human leukemia and lymphoma cells.
• To compare the sensitivity of cancer cells and normal hematopoietic cells to FK228.
• To assess the correlation between HDAC protein expression and FK228 sensitivity.

Main Methods:

• Treatment of human leukemia/lymphoma cell lines and clinical samples with varying concentrations of FK228.
• Assessment of cell viability, G1 arrest, and apoptosis.
• Quantification of IC(50) values for cancer cells and normal hematopoietic cells.
• Analysis of HDAC-1 and HDAC-3 protein expression levels.

Main Results:

• FK228 induced G1 arrest and/or apoptosis in the Raji lymphoma cell line in a dose- and time-dependent manner.
• FK228 demonstrated potent growth inhibition of lymphoid cell lines with IC(50) values ranging from 0.83 to 1.87 ng/ml.
• Clinical samples of acute lymphoblastic leukemia showed a 50% viability decrease at 0.78 ng/ml, while normal cells exhibited higher IC(50) values (2.3-7.8 ng/ml).
• HDAC-1 and HDAC-3 protein levels did not correlate with FK228 sensitivity.

Conclusions:

• FK228 exhibits significant anti-leukemic and anti-lymphoma activity in vitro.
• FK228 demonstrates a favorable therapeutic window, being more potent against cancer cells than normal hematopoietic cells.
• The study suggests FK228 is a potential therapeutic agent for lymphoid malignancies, with achievable in vivo concentrations.